Skip to main content

Table 1 Detail of study regimens

From: A randomized phase II study of weekly nab-paclitaxel plus gemcitabine or simplified LV5FU2 as first-line therapy in patients with metastatic pancreatic cancer: the AFUGEM GERCOR trial

Timing of administration

Day of administration

Drug dose

Arm A

  

H0

1, 8, 15

nab-paclitaxel 125 mg/m2, 30 min IV infusion (maximum infusion time not exceeding 40 min)

H + 0.5

1, 8, 15

gemcitabine 1000 mg/m2 as a 30-min IV infusion

Arm B

  

H0

1, 8, 15

nab-paclitaxel 125 mg/m2, 30 min IV infusion (maximum infusion time not exceeding 40 min)

H + 0.5

1, 15

folinic acid 400 mg/m2 (leucovorin, l + d racemic form, or l form 200 mg/m2) in 250 ml glucose 5 % solution, 2-h IV infusion

H + 2.5

1, 15

5FU bolus 400 mg/m2 in 100 ml glucose 5 % solution, 15 min IV infusion

H + 3

1–2, 15–16

5FU continuous infusion 2400 mg/m2, 46-h IV infusion